SCHEMBL2660907

SCHEMBL2660907

CCSc1ccc2ncnc(Nc3nc4cccnc4s3)c2n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.48
NPC1 O15118 6/20 0.45
RAB9A P51151 4/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 3/20 0.36
GLA P06280 2/20 0.36
GAA P10253 2/20 0.36
RUNX1 Q01196 1/20 0.36
CBFB Q13951 1/20 0.36
PDK1 Q15118 1/20 0.36
EGFR P00533 2/20 0.34
TRPV1 Q8NER1 3/20 0.34
HPGD P15428 3/20 0.33
HTT P42858 2/20 0.33
MKNK2 Q9HBH9 1/20 0.33
ADORA2A P29274 1/20 0.32
RORC P51449 1/20 0.32
DHODH Q02127 1/20 0.32
LCK P06239 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2642784 0.83 NPC1 (0.42) POLBNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL2660906 0.80 POLB (0.38) POLBNPC1RAB9ASMN1; SMN2PDK1
SCHEMBL2642168 0.80 NPC1 (0.53) POLBNPC1RAB9ASMN1; SMN2PDK1
SCHEMBL2642369 0.79 POLB (0.38) POLBNPC1RAB9ASMN1; SMN2PDK1
SCHEMBL2642172 0.79 POLB (0.41) POLBNPC1RAB9ASMN1; SMN2EGFR
SCHEMBL2642149 0.79 NPC1 (0.39) POLBNPC1RAB9ASMN1; SMN2PDK1
SCHEMBL2642518 0.79 GCK (0.48) POLBNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL2642096 0.79 POLB (0.37) POLBNPC1RAB9ASMN1; SMN2HTT
SCHEMBL2642575 0.78 NPC1 (0.38) POLBNPC1RAB9ASMN1; SMN2PDK1
SCHEMBL2642905 0.78 NPC1 (0.38) POLBNPC1RAB9ASMN1; SMN2PDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7687502-B2 Substituted quinazoline or pyridopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-03-30 US disclosed
US-7687502-B2 Substituted quinazoline or pyridopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-03-30 US disclosed
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative MSD K.K. (JP) 2008-02-07 US disclosed
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative MSD K.K. (JP) 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative GCK, GCKR, PDXK POLB 3158/4885NPC1 3557/4885RAB9A 1818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.